Navigation Links
Conatus Pharmaceuticals Completes $20 Million Series B Private Placement Financing
Date:2/11/2011

SAN DIEGO, Feb. 11, 2011 /PRNewswire/ -- Conatus Pharmaceuticals Inc. today announced the closing of a $20 million Series B Preferred Stock private placement financing.  This financing was led by new investor, AgeChem Venture Fund of Montreal, Canada, and included participation by existing investors; Aberdare Ventures, Advent Venture Partners, Bay City Capital, Gilde Healthcare Partners, and Roche Venture Fund.  Conatus will use the proceeds to advance the clinical development of CTS-1027, a novel clinical-stage drug candidate the Company has licensed from F. Hoffman-La Roche, Ltd. and is the subject of multiple Phase 2 clinical trials in hepatitis C (HCV)-infected patients.  

As part of the financing, Louis Lacasse from AgeChem will join the Conatus Board of Directors. "We are very excited about joining such an elite group of investors to support the development of CTS-1027 which we believe could be a blockbuster drug for the treatment of HCV infections," said Louis Lacasse.

Continuing Board Directors are Paul Klingenstein from Aberdare Ventures, Shahzad Malik, M.D., from Advent Venture Partners, William Gerber, M.D., from Bay City Capital, and Marc Perret from Gilde Healthcare, and independent directors, David Hale and Hal Van Wart, Ph.D. Steven J. Mento, Ph.D., Co-founder, President and CEO of Conatus, will continue as Chairman of the Board.

Concurrent with the first closing of the Series B financing, Conatus also converted promissory bridge notes into Series B preferred stock.

The Series B financing will remain open for an additional period as other potential investors conclude their diligence.

"This financing enables Conatus to expand the clinical development of CTS-1027 as a cell-based antiviral for the treatment of HCV infections. We believe that CTS-1027 represents a novel approach to treating HCV disease and look forward to developing this drug candidate in the HCV-null responder population in combinatio
'/>"/>

SOURCE Conatus Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Conatus Pharmaceuticals Reports Positive Results of CTS-1027 in Multiple Preclinical Studies of Liver Disease
2. Conatus Pharmaceuticals Initiates a Second Phase 2 Clinical Trial for the Treatment of Hepatitis
3. Conatus Pharmaceuticals to Present at the Montgomery Healthcare Conference
4. Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV)
5. Conatus Pharmaceuticals Acquires Pfizers Idun Subsidiary
6. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
9. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
10. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
11. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... CARLSBAD, Calif. , July 10, 2014 /PRNewswire/ ... products and services, has launched the FreeRunner™ knee ... runners, who suffer from patella mal-tracking return to ... anatomy differently than other braces, providing support when ... move normally when they don,t. Patellofemoral ...
(Date:7/10/2014)... -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... sale to Galderma of all rights to Restylane, Perlane, ... for $1.4 billion in cash, pursuant to the previously ... acquisition of Galderma. "We are pleased ... company that is firmly committed to the aesthetic dermatology ...
(Date:7/10/2014)... -- Decision Resources Group finds that over half of ... Drug Administration,s (FDA) approval of Vifor Fresenius Medical Care ... by the FDA in November 2013 for the treatment ... dialysis. Other key findings from the report ... : , Bundling: Based ...
Breaking Medicine Technology:Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 3
... 2011 Researchers presented data demonstrating increased specificity ...  MRI for the detection of breast cancer at ... National Interdisciplinary Breast Center Conference held March 12 ... poster presentation, titled Pre-Surgical Detection of Malignancies ...
... Varian Medical Systems (NYSE: VAR ) announced ... fiscal year 2011 following the close of regular trading on ... by a teleconference available to all interested parties at 2:00 ... conference call webcast will be available on the company website ...
Cached Medicine Technology:Researchers Present Key Findings Comparing PEM to MRI for Identification of Contralateral Breast Cancer at the National Consortium of Breast Centers (NCBC) Conference 2Varian Medical Systems Schedules Second Quarter FY2011 News Release and Conference Call 2
(Date:7/11/2014)... 11, 2014 Netmail, ... with its unique Netmail Platform, today announced that ... Conference (WPC), which will be held in Washington’s ... 2014. During the show, Netmail will officially launch ... solution that consolidates email security, archiving, encryption, eDiscovery, ...
(Date:7/11/2014)... July 11, 2014 Based in Pearland, ... to residents of Brazoria County and surrounding counties. Recently, ... clinic is now accessible from Northbound Highway 288 and ... center where patients can get low-cost urgent care of ... from rare, finding places that can match the quality ...
(Date:7/10/2014)... July 11, 2014 The Capital Institute ... performed the first procedure in a clinical trial that ... in the leg. , During the procedure, done at ... an endovascular neurosurgeon, threaded a tiny catheter through the ... body and neck and into the brain. Once the ...
(Date:7/10/2014)... 2014 More than 200 experts on ... urban street violence, will attend the 21st World Meeting ... (ISRA) at the Loews Atlanta Hotel, July 15-19. ... prestigious world meeting, which is held every other year ... bringing together leading scholars from more than 20 different ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 Ticketability.com has a ... and now Paul McCartney tickets for San Diego are being ... San Diego since 1976, and the newly added September 28 ... fans. , Click Here to view the selection ... for Petco Park will become available to the general public ...
Breaking Medicine News(10 mins):Health News:Netmail Heads to Washington, D.C. to Demonstrate New Release of Netmail 5.3 at WPC 2014 July 13-17, 2014 2Health News:Netmail Heads to Washington, D.C. to Demonstrate New Release of Netmail 5.3 at WPC 2014 July 13-17, 2014 3Health News:Prime Urgent Care Announces New Access to the Clinic, Available from Northbound Highway 288 2Health News:New Trial Delivers Chemotherapy to Brain Tumor Through Artery in Leg 2Health News:New Trial Delivers Chemotherapy to Brain Tumor Through Artery in Leg 3Health News:Georgia State Hosts National Conference On Aggression 2Health News:Georgia State Hosts National Conference On Aggression 3Health News:Georgia State Hosts National Conference On Aggression 4Health News:Paul McCartney Tickets for San Diego: Ticketability.com Announces Discounted Tickets for McCartney’s Tour Stop at Petco Park on September 28 2
... the Vrije University in Amsterdam in collaboration with the University of ... , Usually in case of throat cancer the larynx or ... removed. , The patients after this surgery find it ... valve is implanted in-between the windpipe and oesophagus. ,But ...
... If smoking were to be banned by the Government ... home will be affected by passive smoking. Children suffer ... passive smoking. The economists belonging to the University College ... anti-smoking campaigners. ,Smokers will be encouraged ...
... Center for Health Studies of Seattle has revealed that chronic ... as 101 adults who suffer from back pain were assessed ... minutes every week displayed greater progress when compared to those ... ,Yoga has also been found to be more useful than ...
... Angeles County health officials which will facilitate the sending of ... diseases. The site called, inSPOTLA.org is meant // to check ... site is targeted at people seeking casual sex on line. ... in 2004 has resulted in as many as 20,000 e-mails. ...
... A new report has revealed that wild thrashing during ... of Parkinson's disease. Professor Claudia Trenkwalder said that disruptions ... could be a signal to approaching Parkinson's disease, according ... muscles are normally relaxed and disconnected from motor controls ...
... The cervical cancer vaccine, Cervarix, appears to work best in ... GlaxoSmithKline (GSK). ,The vaccine targets the human papilloma virus, ... it works pretty well in the 15-25 age group as ... high as that found in this group. This appears to ...
Cached Medicine News:
... a completely automated instrument that offers Rapid ... 6 hour same day turnaround), random or ... It is used for bacterial and yeast ... and has a complete data management system. ...
IDS Rapid One, a microbial identification system....
The Cogent Microbial Luminescence System (MLS) is a superior Rapid microbial detection system for UHT product screening combining proven technology of ATP-bioluminescence with unsurpassed hardware in...
... SkanWasher 300 is an ... designed to give reliable, ... cross-contamination between wells, and ... to plate. The washer ...
Medicine Products: